Shares in French peanut allergy specialist DBV Technologies (Euronext: DBV) were boosted 20% in pre-market trading on Thursday, after the firm announced positive topline results from the Phase III PEPITES trial.
DBV is testing the efficacy and safety of investigational Viaskin Peanut in peanut-allergic children ages four to 11 years.
The results show long-term clinical benefit, as demonstrated by an increase in eliciting dose (ED), which could decrease the chance of reacting to accidental peanut exposure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze